BERWYN, Pennsylvania–(BUSINESS WIRE)–Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in the development of product candidates for pain management, CNS disorders and antiviral indications, announced positive results from four preclinical skin safety studies for Epoladerm™ (diclofenac epolamine). Epoladerm is an investigational product candidate for the management of pain associated with osteoarthritis of the knee. From these recently concluded animal studies, the researchers concluded that dermal administration of Epoladerm once daily for 28 days was well tolerated with no serious adverse effects.
The studies were performed by Charles River Laboratories, a well-known clinical research organization. The studies included a skin irritation study in rabbits; an assessment of skin sensitization in guinea pigs; and a mouse fibroblast phototoxicity assay. Epoladerm was well tolerated in each of the studies with no reportable skin irritation, skin sensitization or phototoxicity observed.
“These successful preclinical results should further strengthen Virpax’s anticipated investigational new drug demand for Epoladerm prior to the expected start of first-in-human trials,” said Anthony P. Mack, President and CEO of Virpax.
Virpax Pharmaceuticals is developing Epoladerm™ (diclofenac epolamine), an investigational pain reliever supplied in a pre-filled device for administration as a topical spray film to manage chronic pain associated with osteoarthritis of the knee. The company’s proprietary technology aims to provide a convenient spray can for applying the spray film to the knee. The film obtained is thinner than a standard liquid dressing, visibly clear and quick-drying. The spray formulation is intended to avoid awkward and messy application of creams or gels to the knee.
About Virpax Pharmaceuticals
Virpax is developing branded product candidates for the non-addictive management of pain and neurological disorders using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval for its three patented drug delivery platforms. Epoladerm™ is a topical spray film formulation of diclofenac being developed to manage the pain of osteoarthritis. Probudur™ is a long-acting single injection liposomal bupivacaine formulation being developed to manage postoperative pain. Envelta™ is an intranasal enkephalin formulation based on molecular envelope technology (MET) being developed for the management of acute and chronic pain, including pain associated with cancer, as well as post stress disorder. -traumatic (PTSD) under the name of PES200. MET technology is also used in AnQlar™, a product candidate intended to inhibit viral replication caused by influenza or SARS-CoV-2. Virpax recently acquired worldwide rights to VRP324, a product candidate for the nasal delivery of a pharmaceutical grade cannabidiol (CBD) for the management of epilepsy in children (a rare pediatric disease) and adults. For more information, please visit www.virpaxpharma.com.
#Virpax #Successfully #Completes #Preclinical #Dermal #Safety #Studies #Epoladerm #Medical #Marijuana #Program #Connection